Calosyn Pharma
OperatingCALOSYN PHARMA, INC.
Biotech · Sharon, MA
Calosyn Pharma is a pre-revenue company developing a long-acting, sustained-release injection for osteoarthritis (OA) using a mechanism with clinical-stage validation and IP protection.
Financials
FY2023–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Cap table
Share counts as of Dec 31, 2024| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 5,446,409 | — | 100.0% | — |
Sold to the crowd
- Reg CF · Sep 2025Crowdfunding Stock$126.9K· 18 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
7 people
PhD in drug delivery systems, founder of Sciebus Consulting, and MBA with a focus on pharmaceutical entrepreneurship. In addition to working over 80 hours per week for Calosyn, he also works one to two hours per month as the Owner of Sciebus Consulting LLC and as Board Treasurer for Advanced Air Mobility Institute.
20+ years in life sciences venture finance, former CFO of Medical Science Partners, and ex-manager at Ernst & Young.
Harvard-trained physician with leadership roles in multiple biotech firms; expert in FDA strategy.
Joseph F. Lovett has been in the life sciences industry since 1970 with three corporations (CR Bard, Mallinckrodt & Damon Biotech. Since 1988, Mr. Lovett has been in the venture Capital business with three venture capital funds (Medical Science Partners I-III with Harvard as an affiliate) and Louisiana Funds I&II with the LSU Research, Technology & Science Foundation as an affiliate).
Board member since August 2025. Founding investor and managing partner at Cancer Focus Fund, a venture capital firm investing in oncology and life sciences.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 1 annual reports (FY2025)
Missing: 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-UMar 2, 20260001429819-26-000001EDGAR
- Form C/ADec 19, 20250001429819-25-000007EDGAR
- Form CSep 30, 20250001429819-25-000003EDGAR
- Form DMar 7, 20240001429819-24-000004EDGAR
- Form DFeb 29, 20120001429819-12-000002EDGAR
- Form D/AApr 13, 20100001429819-10-000001EDGAR
- Form DApr 13, 20090001429819-09-000003EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.